Biogen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIIB research report →
About the company
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.
- CEO
- Christopher A. Viehbacher
- IPO
- 1991
- Employees
- 7,605
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $29.53B
- P/E
- 21.46
- P/S
- 3.00
- P/B
- 1.58
- EV/EBITDA
- 11.73
- Div Yield
- 0.00%
- Gross Margin
- 69.77%
- Op Margin
- 15.65%
- Net Margin
- 13.92%
- ROE
- 7.55%
- ROIC
- 5.44%
- Revenue
- $9.81B · 1.39%
- Net Income
- $1.29B · -20.76%
- EPS
- $8.85 · -20.98%
- Op Income
- $1.88B
- FCF YoY
- -18.48%
- 52W High
- $205.97
- 52W Low
- $121.05
- 50D MA
- $188.79
- 200D MA
- $173.46
- Beta
- 0.18
- Avg Volume
- 1.17M
Get TickerSpark's AI analysis on BIIB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | HAWKINS WILLIAM A | other | 1,505 |
| Jun 9, 26 | SHERWIN STEPHEN A | other | 1,505 |
| Jun 9, 26 | Rowinsky Eric K | other | 1,505 |
| Jun 9, 26 | Mantas Jesus B | other | 1,505 |
| Jun 9, 26 | LANGER SUSAN | other | 1,505 |
| Jun 9, 26 | Patolawala Monish D | other | 1,505 |
| Jun 9, 26 | Pangalos Menelas N | other | 1,505 |
| Jun 9, 26 | Pangalos Menelas N | other | 2,370 |
| Jun 9, 26 | Pangalos Menelas N | other | 2,370 |
| Jun 9, 26 | Minor Lloyd | other | 1,505 |
Our BIIB coverage
Recent articles, reports, and earnings notes.
Biogen (BIIB): Turnaround Gains Traction as Growth Mix Improves
Biogen is no longer just a declining MS story. Q1 2026 showed rising EPS, stronger free cash flow, and growing newer products, but full-year revenue still faces pressure.
Biogen Inc. (BIIB) drops 6% after mixed Alzheimer’s data
Biogen Inc. (BIIB) drops sharply after mixed Phase 2 Alzheimer’s trial results for diranersen, also known as BIIB080. The stock fell on heavy volume as investors focused on the missed primary endpoint, even though the study showed encouraging biomarker and cognitive signals and the program may still advance.
Want a deeper read on BIIB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.